AI And The Continuum Of Care

A recent Forbes panel convened healthcare leaders to tackle the most pressing issues around AI in the continuum of care—from clinician augmentation and cybersecurity to regulation and governance. The discussion underscored that while AI promises to revolutionize patient journeys, trust remains the single biggest barrier to adoption. Without transparent governance and robust security, even the most powerful clinical algorithms will fail to earn the confidence of providers and patients alike.

Trust is the linchpin of AI in healthcare. The panel, featuring experts from health systems, technology firms, and regulatory bodies, zeroed in on how to build confidence at every stage of the care continuum—from preventative screenings to chronic disease management and end-of-life planning. The high stakes of medical decision-making demand that AI systems not only be accurate but also explainable and fair. The group emphasized that clinician augmentation, not replacement, is the most viable path forward, allowing physicians to leverage AI for tasks like radiology interpretation, risk stratification, and administrative workflows.

The timeline for this push is now. Healthcare organizations are under immense pressure to digitize and automate, exacerbated by staffing shortages and rising costs. The panel noted that the pandemic accelerated the adoption of telemedicine and remote monitoring, creating a foundation for AI to plug into existing digital health infrastructure. However, cybersecurity emerged as a major concern. With patient data flowing through more points in the continuum, the attack surface widens. The experts called for “medical-grade AI” that meets the same rigorous standards as medical devices.

Key details from the panel: participants highlighted that trust isn’t just about technical performance—it’s about transparency in algorithms, data privacy, and accountability when things go wrong. Governance frameworks must be co-developed with clinicians, regulators, and patients. The panel referenced emerging models, such as the FDA’s evolving framework for AI/ML-based medical devices, but stressed that international harmonization is lacking. Cybersecurity threats, including adversarial attacks on diagnostic models, were cited as a growing risk that regulatory bodies are still catching up to. The concept of the “AI continuum of care” was central, encompassing not just acute care but also long-term monitoring and home health.

Analysis shows that the panel’s insights align with broader industry trends. A study published earlier this year found that 84% of healthcare executives believe AI will be critical to their organization’s strategy within three years, yet only 25% feel their systems are adequately protected against AI-specific cyber threats. The gap between ambition and readiness is a recurring theme. Experts argue that without a shared lexicon for “trustworthy AI,” efforts across different care settings will remain fragmented. The continuum of care demands interoperability—not just of data formats, but of ethical standards and safety protocols.

Looking ahead, the panelists agreed that the next 12 to 24 months will be pivotal. They anticipate more regulatory clarity from bodies like the FDA, EMA, and national health ministries. Pilot programs integrating AI into clinical workflows will increase, with a focus on measuring not just accuracy but also clinician and patient satisfaction. The emergence of generative AI in clinical notes and patient communication will force new conversations about liability and authenticity. Ultimately, the success of the AI continuum of care hinges on collaboration—between technologists, doctors, policymakers, and the public. The wheel is turning, but trust must be earned every step of the way.